In breast cancer (bc), ACE2 has been shown to inhibit angiogenesis, a key process in tumor progression and metastasis, by suppressing the vascular endothelial growth factor A (VEGFA)/VEGFR2/ERK signaling pathway [16]. Here, VEGFA is linked to breast carcinoma.